Thursday 16 October, 2025
Introduction: Monoclonal antibodies (mAbs) exposure-response relationship in oncology is complex and associated with an important inter-individual variability [1–3]. Several confounding…
Read moreAbstracts
Pharmacokinetic-pharmacodynamic modelling to characterize the time-course of meropenem effect in vivo on bacteria with high MIC
Thursday 16 October, 2025
Objectives: Carbapenem resistance represents a serious clinical concern, with multiple carbapenem-resistant species listed as a critical priority for research by…
Read moreTranslation of the in vitro antimicrobial activity of afabicin against Staphylococcus aureus to in vivo bacterial killing dynamics using a pharmacokinetic-pharmacodynamic model based on time-kill experiments
Thursday 16 October, 2025
Introduction: Afabicin is a prodrug of afabicin desphosphono, a first-in-class antibiotic. Afabicin desphosphono is an enoyl-acyl carrier protein reductase (FabI)…
Read morePharmacokinetics of cycloserine in an Indian population with multidrug-resistant tuberculosis.
Thursday 16 October, 2025
Introduction: Cycloserine (CYC) inhibits alanine racemase and D-alanine ligase, two essential enzymes for the cell wall synthesis in Mycobacterium tuberculosis…
Read moreA semi-mechanistic model to characterize the long-term dynamic of HBV markers during treatment with lamivudine and PEG-IFNa
Thursday 16 October, 2025
Objectives: Current treatments for chronic HBV (CHB) infection rely on nucleosid analogs (NUCs) and pegylated interferon (peg-IFNα). These treatments suppress…
Read moreA mechanistic model to characterize the long-term dynamic of HBV markers in Lamivudine and PEG-IFNa treated patients
Thursday 16 October, 2025
Objectives: Chronic hepatitis B remains a major public health threat due to its high infectiousness and its progression to cirrhosis,…
Read moreMechanistic modeling of the long-term dynamics of viral markers to predict the outcome of combination therapy in chronic HBV and HDV infections
Thursday 16 October, 2025
Background. Nearly 300 million people worldwide are chronically infected with Hepatitis B virus (HBV). One important specificity of HBV is…
Read moreEvaluation in model averaging: an application to viral dynamic models
Thursday 16 October, 2025
Objectives: The use of model averaging (MA) over model selection (MS) has already shown its advantages as it accounts for…
Read moreImpact of sampling times on the predictive performance of tobramycin population pharmacokinetic models
Thursday 16 October, 2025
Introduction External evaluations are the most stringent methods for evaluating the predictive performance of population pharmacokinetic (PK) models. Our previous…
Read moreDoes sample size, sampling strategy, or handling of concentrations below the lower limit of quantification matter when externally evaluating population pharmacokinetic models?
Thursday 16 October, 2025
Objectives: As precision dosing becomes increasingly prevalent in clinical practice, selecting the most appropriate population pharmacokinetic (popPK) model for a given…
Read more